Bluebird Bio Inc. (NASDAQ:BLUE) insider Eric Sullivan sold 416 shares of the stock in a transaction dated Tuesday, September 13th. The shares were sold at an average price of $59.00, for a total transaction of $24,544.00. Following the completion of the sale, the insider now directly owns 5,891 shares in the company, valued at $347,569. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Eric Sullivan also recently made the following trade(s):

  • On Wednesday, August 3rd, Eric Sullivan sold 416 shares of Bluebird Bio stock. The shares were sold at an average price of $59.00, for a total transaction of $24,544.00.
  • On Wednesday, July 27th, Eric Sullivan sold 2,912 shares of Bluebird Bio stock. The shares were sold at an average price of $55.01, for a total transaction of $160,189.12.
  • On Wednesday, July 20th, Eric Sullivan sold 2,807 shares of Bluebird Bio stock. The shares were sold at an average price of $45.04, for a total transaction of $126,427.28.

Bluebird Bio Inc. (NASDAQ:BLUE) opened at 71.47 on Monday. The company’s market capitalization is $2.66 billion. Bluebird Bio Inc. has a 52 week low of $35.37 and a 52 week high of $143.08. The company’s 50-day moving average price is $54.41 and its 200 day moving average price is $47.27.

Bluebird Bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.15. The firm had revenue of $1.55 million for the quarter, compared to analyst estimates of $2.01 million. Bluebird Bio had a negative net margin of 3,512.13% and a negative return on equity of 24.85%. The firm’s quarterly revenue was down 68.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.57) earnings per share. On average, equities research analysts anticipate that Bluebird Bio Inc. will post ($6.16) EPS for the current year.

A number of research analysts have issued reports on BLUE shares. Goldman Sachs Group Inc. upgraded shares of Bluebird Bio from a “buy” rating to a “conviction-buy” rating and set a $135.00 target price on the stock in a report on Thursday. Maxim Group restated a “buy” rating and issued a $85.00 price target (down previously from $105.00) on shares of Bluebird Bio in a report on Thursday, August 4th. BTIG Research restated a “buy” rating and issued a $72.00 price target on shares of Bluebird Bio in a report on Wednesday, June 29th. Jefferies Group restated a “positive” rating and issued a $80.00 price target on shares of Bluebird Bio in a report on Thursday, July 14th. Finally, Wedbush restated an “outperform” rating and issued a $117.00 price target on shares of Bluebird Bio in a report on Thursday, September 8th. Six research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Bluebird Bio presently has a consensus rating of “Buy” and a consensus target price of $87.39.

Several large investors have recently made changes to their positions in BLUE. Baillie Gifford & Co. raised its stake in shares of Bluebird Bio by 1.5% in the second quarter. Baillie Gifford & Co. now owns 5,054,175 shares of the company’s stock valued at $218,795,000 after buying an additional 76,538 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Bluebird Bio by 14.2% in the second quarter. Vanguard Group Inc. now owns 2,680,871 shares of the company’s stock valued at $116,055,000 after buying an additional 333,396 shares in the last quarter. State Street Corp raised its stake in shares of Bluebird Bio by 41.4% in the second quarter. State Street Corp now owns 1,699,977 shares of the company’s stock valued at $73,592,000 after buying an additional 498,041 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of Bluebird Bio by 80.0% in the second quarter. BlackRock Fund Advisors now owns 1,386,229 shares of the company’s stock valued at $60,010,000 after buying an additional 616,095 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new stake in shares of Bluebird Bio during the first quarter valued at about $51,095,000.

About Bluebird Bio

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

5 Day Chart for NASDAQ:BLUE

Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.